Tags: Drug.

Pardoprunox (SLV-308) is an antiparkinsonian drug currently under development by Solvay for the treatment of Parkinson’s disease and as of March 2010 is in Phase III clinical trials. It was also being investigated for the treatment of depression and anxiety but these indications appear to have been abandoned.Pardoprunox acts as a D2 (pKi = 8.1) and D3 receptor (pKi = 8.6) partial agonist (IA = 50% and 67% respectively) and 5-HT1A receptor (pKi = 8.5) full agonist (IA = 100%).

Pardoprunox.png
ATC prefix
none
CAS number
269718-84-5
FDA UNII code
5R72CHP32S
IUPAC name
7-(4-methylpiperazin-1-yl)-3H-13-benzoxazol-2-one
PubChem
6918524

Loading...

This page contains content from the copyrighted Wikipedia article "Pardoprunox"; that content is used under the GNU Free Documentation License (GFDL). You may redistribute it, verbatim or modified, providing that you comply with the terms of the GFDL.